Toripalimab plus Anlotinib
Phase 3Small molecule
Toripalimab plus Anlotinib is one of 6 small molecule programs targeting Toripalimab. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Toripalimab
#DrugCompanyPhaseTrials
1Tuoyi
CCoherus Oncology, Inc.
Phase 2
Trodelvy
GileadPhase 2
JS004
SShanghai Pulmonary Hospital, Shanghai, China
Phase 2
Toripalimab plus Anlotinib
TTaizhou Hospital
Phase 3
Actinomycin D
PPeking Union Medical College Hospital
Phase 2
RC108
RRemeGen Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Toripalimab plus Anlotinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTaizhou Hospital